Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 86.62M shares rose 1.2% year over year, in line with the +1.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.2% toward the trailing-twelve-month pace of +1.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
86.62M+0.0% QoQ
Last fiscal yearDec 2025
86.63M+1.2% YoY
LTMMar 2026
86.55M+1.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.2%——
1 year+1.2%——
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
86.63M USD
Year-over-year change
+1.2%
4-year CAGR
+13.6%

Weighted Avg Shares (Diluted) vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's LTM Mar 2026 weighted avg shares (diluted) of 86.55M shares is the 7th highest of the 11 companies compared; the peer median is 90.82M shares.
  • Its year-over-year change of +1.2% is the 9th highest of 11, against a peer median of +14.7%.
  • Over three fiscal years its annual growth of +12.5% compares with a peer median of +14.9%.
SNDX Competitors Peer median
Weighted Avg Shares (Diluted) for SNDX and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026353.26M +9.5%+16.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.2%+28.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
REPLReplimune Group, Inc.LTM Dec 202589.05M +21.7%+15.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
ZYMEZymeworks Inc.LTM Sep 202674.82M -1.6%+4.9%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
Peer median (excluding SNDX) 90.82M+14.7%+14.9%

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.71M0023.68M172.35M
Cost of Revenue000826K6.97M
Gross Profit139.71M0022.85M165.38M
Gross Margin100.0%——96.5%96.0%
Research & Development88.25M118.5M163.03M241.65M258.78M
Selling, General & Admin25.24M33.26M66.92M120.88M179.68M
Operating Expenses113.49M151.76M229.95M362.53M438.47M
Depreciation & Amortization43K33K12K8K6K
EBITDA26.87M(146.17M)(209.14M)(313.82M)(251.63M)
EBITDA Margin19.2%——-1325.3%-146.0%
Operating Income26.22M(151.76M)(229.95M)(339.67M)(273.08M)
Operating Margin18.8%——-1434.4%-158.4%
Interest Income403K5.87M21.16M26.09M22.73M
Interest Expense1.9M3.14M208K4.93M33.79M
Other Income / Expenses(1.29M)2.42M20.59M20.91M(12.34M)
Income Before Tax24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Pre-Tax Margin17.8%——-1346.1%-165.6%
Income Tax Expense00000
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Net Margin17.8%——-1346.1%-165.6%
EPS (Basic)0.48(2.46)(2.98)(3.73)(3.29)
EPS (Diluted)0.48(2.46)(2.98)(3.73)(3.29)
Weighted Avg Shares52.06M60.76M70.37M85.62M86.63M
Weighted Avg Shares (Diluted)52.06M60.76M70.37M85.62M86.63M

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.